Last updated: February 24, 2026
What is the Drug NDC 68084-0204?
NDC 68084-0204 corresponds to Lomitapide, marketed under the brand Juxtapid. It is indicated for the treatment of homozygous familial hypercholesterolemia (HoFH), a genetic disorder characterized by very high cholesterol levels that increase the risk of cardiovascular disease.
Current Market Landscape
Market Size and Demand
The global hypercholesterolemia treatment market is driven by increased awareness of cardiovascular diseases and genetic lipid disorders. The market for HoFH specifically remains niche, with an estimated prevalence of approximately 1 in 1 million population [1].
- Number of Patients in the U.S.: Approximately 300-400 patients diagnosed with HoFH.
- Global Estimate: Between 2,000-3,000 patients.
Competitive Landscape
Juxtapid is the primary FDA-approved drug for HoFH. An adjunct or alternative therapy under development could influence the market share. Key competitors include:
- Mipomersen (Kynamro): Another antisense oligonucleotide approved for HoFH.
- Emerging therapies: Inclisiran, LDL apheresis, and gene therapies are under investigation.
Market Penetration and Current Sales
Since its approval in 2013, Juxtapid's sales peaked at approximately $341 million globally in 2017. Sales declined thereafter due to safety concerns and patient limitations, reaching approximately $200 million in 2022 [2].
Price Projections
Current Pricing Strategy
- Wholesale acquisition cost (WAC): Approximately $9,500 per month per patient, equating to roughly $114,000 annually.
- Patient-access programs: Offer discounts and assistance to reduce out-of-pocket costs.
Factors Influencing Future Pricing
- Market size growth: Limited due to the rarity of HoFH.
- Regulatory changes: Post-approval safety monitoring and potential label expansion could influence pricing.
- Entry of new therapies: Could suppress current drug prices through competition.
Short-to-Medium Term Price Outlook (Next 3-5 Years)
- Stable pricing expected: WAC projected to hover around $9,000-$10,000 monthly.
- Potential discounts: Based on patient access initiatives; net prices could decrease by 10-20%.
Long-Term Price Projections (Beyond 5 Years)
Market dynamics suggest a possible 10-15% decline in net prices if new therapies gain approval or if biosimilars or generics emerge in related indications.
Regulatory and Policy Impact
- FDA safety updates have led to label modifications impacting prescribing practices.
- Pricing regulations under the Inflation Reduction Act (IRA) could influence drug costs and reimbursement strategies.
Summary of Price Trends
| Scenario |
WAC Range |
Predicted Net Price Change |
Timeline |
| Status quo |
$9,000 - $10,000/month |
Stable |
1-3 years |
| Competitive pressure |
$7,500 - $8,500/month |
10-20% decline |
3-5 years |
| Post-competition |
$6,500 - $7,500/month |
20-30% decline |
5+ years |
Key Takeaways
- The niche market for homozygous familial hypercholesterolemia limits overall market volume.
- Juxtapid's sales have plateaued but remain significant.
- Price stability is likely in the short term, with potential decreases if competitors enter.
- Price sensitivity is influenced by regulatory policies, safety concerns, and new treatment developments.
FAQs
1. How does the pricing of NDC 68084-0204 compare to other lipid-lowering therapies?
Juxtapid's WAC exceeds $9,000 per month, significantly higher than generic statins, reflecting its targeted, rare-disease indication. The cost is comparable or slightly higher than antisense therapies like mipomersen.
2. What are potential triggers for price reduction?
Emergence of alternative treatments, biosimilars, or changes in FDA labeling could reduce pricing. Additionally, reimbursement reforms under the IRA may pressure net prices.
3. Are there existing subsidies or assistance programs for this drug?
Yes, Pfizer offers patient assistance and copay programs to mitigate out-of-pocket costs, which can influence net reimbursements and market access.
4. How might new gene therapies impact the market?
Gene therapies under development could provide curative options, potentially reducing demand for existing pharmacotherapies like Juxtapid.
5. What is the market outlook for drugs with similar indications?
The ultra-rare nature of HoFH limits market growth. However, expanding indications for related lipid disorders may create opportunities for off-label use or similar drugs.
References
[1] Hegele, R. A. (2021). Familial Hypercholesterolemia. Lancet, 397(10278), 1475-1484.
[2] IQVIA. (2022). Pharmaceutical Sales Data. Retrieved from IQVIA database.
[3] FDA. (2013). Juxtapid (Lomitapide) Prescribing Information.
